StockNews.com Initiates Coverage on DBV Technologies (NASDAQ:DBVT)

StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report issued on Thursday. The firm set a “hold” rating on the stock.

Several other equities research analysts also recently commented on the company. HC Wainwright lifted their price objective on DBV Technologies from $25.00 to $35.00 and gave the stock a “buy” rating in a report on Thursday, October 24th. JMP Securities reaffirmed a “market outperform” rating and issued a $10.00 target price on shares of DBV Technologies in a report on Tuesday, December 10th.

DBV Technologies Stock Performance

Shares of DBVT stock opened at $3.83 on Thursday. The company has a market capitalization of $78.78 million, a price-to-earnings ratio of -0.85 and a beta of 0.64. The company’s 50-day moving average is $3.29 and its 200 day moving average is $3.82. DBV Technologies has a one year low of $2.20 and a one year high of $9.50.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.